ClinicalTrials.gg
CompletedNCT01771822Updated Feb 28, 2013

Ibuprofen 5% Topical Gel CIPT

A Phase 1 interventional study of Ibuprofen 5% topical gel and Topical gel vehicle in Pain, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-02-28.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
62nd of 86
50 · median 100
Started
2013
with 3 others
Phase 1
9 of 86
none open now
Registered
34th of 86
by date
Lead sponsor
8 of 86
Pfizer

Among the 86 studies testing ibuprofen in Pain, this one is the 62nd largest by enrollment, is one of 4 that started in 2013, is one of 9 in phase 1, and was the 34th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

This study will determine the potential of Ibuprofen 5% Topical Gel and its vehicle gel to cause irritation after repeated topical application to the healthy skin of human subjects under controlled conditions.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • cumulative irritancy patch test (CIPT)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy male and/or female subjects (to be confirmed by medical history) 18 years of age or older, female subjects of and males who are using an acceptable form of , subjects who are free of any systemic or dermatologic disorder

Exclusion criteria

Exclusion Criteria:

Have skin disease at the application site, not willing to stop use of systemic or topical analgesics, , or antihistamines, unwilling or unable to stop use of sunscreens, creams, or similar products on the back during the study

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Ibuprofen 5% topical gel

    Drug: Ibuprofen 5% topical gel

  • Experimental
    Topical gel vehicle

    Drug: Topical gel vehicle

  • Active comparator
    Sodium lauryl sulfate 0.2%

    Drug: Sodium lauryl sulfate 0.2%

  • Sham comparator
    Sodium chloride solution 0.9% (saline)

    Drug: Sodium chloride solution 0.9% (saline)

Interventions

  • 0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions

  • DrugTopical gel vehicle

    0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions

  • DrugSodium lauryl sulfate 0.2%

    0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions

  • DrugSodium chloride solution 0.9% (saline)

    0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions

06

What researchers measure

Primary outcomes

  1. Assessment of local skin irritation at patch sites

    Time frame: Daily for 21 days, Days 2 through 22

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Days 1 through 22, + 28 days after last product administration

07

Study locations

1 site
  • Pfizer Investigational Site
    Carlstadt, New Jersey 07652, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2012
First posted
Jan 18, 2013
Start
Jan 2013
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Last update
Feb 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01771822
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 18, 2013
Start date
Jan 2013
Primary completion
Feb 2013
Completion
Feb 2013
Last update
Feb 28, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion